A 52-year-old man with a 10-year history of Type 2 diabetes presents for routine follow-up. His fasting glucose is 156 mg/dL and HbA1c is 7.8%. He is currently on metformin and glibenclamide. To assess his current risk of microvascular complications and guide intensification of therapy, which investigation is most appropriate?